Hurricane Electric Expands Global Network to The Albanian Internet Exchange
Hurricane Electric, the world’s largest IPv6-native Internet backbone announced today that it has further expanded its presence in Southeastern Europe by connecting to the Albanian Neutral Internet eXchange (ANIX).
ANIX is the first neutral and not-for-profit Internet Exchange point in Albania and is hosted and managed by Namex in the carrier-grade data center of RASH, the Albanian Academic Network, in Tirana. ANIX went live in March 2018. Prior to the establishment of ANIX, traffic between Albanian endpoints had to pass through foreign countries. ISPs throughout Albania and the world come to ANIX to interconnect their networks.
Hurricane Electric’s presence in ANIX will provide reduced latency and improved fault tolerance, load balancing and congestion management infrastructure. The added direct connectivity paths also increase the reach of Hurricane Electric’s next-generation (IPv6) Internet infrastructure and services. Additionally, ANIX members can now exchange IP traffic, or “peer,” with Hurricane Electric’s rich global Internet backbone.
Namex is an Internet Exchange Point based in Rome, Italy, established in 1995. Namex and RASH, the Albanian Academic Network, established in 2007, have been conducting the ANIX pro-bono effort to improve the connectivity of Albanian ISPs to each other and to the global Internet. ANIX features state-of-the-art devices, installed in the RASH data center which is equipped with numerous features to ensure uptime, including N + 1 UPS, temperature and humidity sensors, and real-time monitoring of the facility’s critical infrastructure.
In addition to providing increased network capacity through 100GE (100 Gigabit Ethernet), 10GE (10 Gigabit Ethernet) and GigE (1 Gigabit Ethernet) ports, Hurricane Electric’s vast global network, offers over 20,000 BGP sessions with over 9,000 different networks via more than 250 major exchange points and thousands of customers and private peering ports.
“Hurricane Electric’s is excited to connect to ANIX while expanding our footprint in Southeastern Europe," said Mike Leber, President of Hurricane Electric. “The new connection will enable local ISPs and other networks to take advantage of Hurricane Electric’s rich global network, while helping to strengthen Albania’s Internet connectivity.”
About Hurricane Electric
Hurricane Electric operates its own global IPv4 and IPv6 network and is considered the largest IPv6 backbone in the world. Within its global network, Hurricane Electric is connected to over 250 major exchange points and exchanges traffic directly with more than 9,000 different networks. Employing a resilient fiber-optic topology, Hurricane Electric has no less than five redundant 100G paths crossing North America, four separate 100G paths between the U.S. and Europe, and 100G rings in Europe and Asia. Hurricane also has a ring around Africa and a ring through Australia and New Zealand. Hurricane Electric offers IPv4 and IPv6 transit solutions over the same connection. Connection speeds available include 100GE (100 gigabits/second), 10GE, and gigabit ethernet. Additional information can be found at http://he.net.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220523006059/en/
Contact information
Media
Adam Waitkunas
Milldam Public Relations
adam.waitkunas@milldampr.com
(978) 828-8304
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics to Present Broad Range of Clinical, Real-World and Mechanistic Data at TOXINS 20268.12.2025 09:00:00 EET | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced that the company will present more than 20 clinical and non-clinical abstracts and posters spanning spasticity, movement disorders, and neurotoxin science at the TOXINS 2026 8th International Conference, taking place January 14–17, 2026, in Madrid, Spain. These presentations underscore the company’s commitment to addressing unmet needs in neurological disorders. “Our research reflects a relentless focus on improving patient outcomes through innovation in neurotoxin science,” said Dr. Stefan Albrecht, Chief Scientific and Medical Officer at Merz Therapeutics. “By presenting these new data at TOXINS 2026, we aim to foster scientific exchange and advance treatment strategies that address real-world challenges for patients and clinicians.” Merz Therapeutics will share new findings reflecting its continued dedication to advancing neurotoxin science. These include: Lower Limb Spasticity Incobotulinumto
Galderma Welcomes Increased Equity Investment From L’Oréal8.12.2025 08:05:00 EET | Press release
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that L’Oréal Groupe intends to increase its equity investment in the company, acquiring an additional 10% stake from Sunshine SwissCo GmbH (a consortium led by EQT, Abu Dhabi Investment Authority (ADIA), and Auba Investment Pte. Ltd., acting as sellers). Following the transaction, which is subject to customary approvals, L’Oréal’s total shareholding in Galderma will rise to 20%, building on its initial investment made in August 2024. The transaction is expected to close in Q1 2026. In connection with this increased investment, Galderma will consider nominating two non-independent board candidates from L’Oréal, replacing the board members representing the consortium led by EQT, at the 2026 Annual General Meeting. Additionally, Galderma and L’Oréal aim at exploring additional scientific research projects of mutual interest. This ongoing collaboration brings together Galderma’s scientific leadership i
Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 05:37:00 EET | Press release
Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the National Institute of Standards and Technology (NIST) show that many commercial facial recognition algorithms have significantly higher error rates for women and people of colour largely due to underrepresentation in datasets AI algorithms are trained on. Biased algorithms lead to unfair denials of service and create security vulnerabilities. The competition at the Conference on Neural Information Processing Systems, among the world’s most prestigious AI con
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
